Work

Efficacy and Safety of Inotuzumab Ozogamicin in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated in the INO-VATE Trial: Outcomes by Salvage-Treatment Phase

Year: 2019

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2019.07.035

Authors: Elias Jabbour, Matthias Stelljes, Anjali Advani, Daniel DeAngelo, Nicola Gökbuget, David Marks, Wendy Stock, Susan O’Brien, Ryan Cassaday, Tao Wang, Alexander Neuhof, Erik Vandendries, Hagop Kantarjian

Institutions: The University of Texas MD Anderson Cancer Center, University Hospital Münster, Cleveland Clinic, Dana-Farber Cancer Institute, Goethe University Frankfurt, University of Chicago, University of California, Irvine, UC Irvine Chao Family Comprehensive Cancer Center, University of Washington, Fred Hutch Cancer Center, Pfizer (United States), Pfizer (Germany)

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2970311002

FWCI:

Cites:

Cited by:

Related to: 10